-
公开(公告)号：US20240009319A1
公开(公告)日：2024-01-11
申请号：US18347280
申请日：2023-07-05
Applicant: RINAT NEUROSCIENCE CORP.
Inventor： Santiago Esteban FARIAS , Meritxell GALINDO CASAS , Pavel STROP
IPC: A61K47/68
CPC classification number: A61K47/6803 , A61K47/68 , A61K47/6817 , A61K47/6809 , A61K47/6805
Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates) comprising specific acyl donor glutamine-containing tags and amine donor agents. The invention also provides methods of making such engineered polypeptide conjugates using transglutaminase and methods of using thereof.
-
公开(公告)号：US20220249657A1
公开(公告)日：2022-08-11
申请号：US17725199
申请日：2022-04-20
Applicant: RINAT NEUROSCIENCE CORP.
Inventor： Yasmina Noubia Abdiche , Helen Kim Cho , Wei-Hsien Ho , Karin Ute Jooss , Arvind Rajpal , Sawsan Youssef
IPC: A61K39/39 , A61K39/395 , A61K45/06 , A61K39/00 , C07K16/28
Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
-
公开(公告)号：US10155037B2
公开(公告)日：2018-12-18
申请号：US14958053
申请日：2015-12-03
Applicant: RINAT NEUROSCIENCE CORP.
Inventor： Yasmina Noubia Abdiche , Weihsien Ho , Arvind Rajpal , Sawsan Youssef
IPC: C07K16/28 , A61K39/395 , A61K39/39 , A61K45/06 , A61K39/00
Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
-
公开(公告)号：US20180099054A1
公开(公告)日：2018-04-12
申请号：US15573303
申请日：2016-05-12
Applicant: PFIZER INC. , RINAT NEUROSCIENCE CORP.
Inventor： ASHWIN GOLLERKERI , KAREN VELASTEGUI , RAFFAELE BAFFA , JAYMES SCOT HOLLAND
CPC classification number: A61K47/50 , A61K47/6809 , A61K47/6849 , A61K48/0083 , A61K2039/505 , A61P35/00 , C07K16/28 , C07K2317/53 , C07K2317/565 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides for dosing regimens for the treatment of patients with cancer and/or an EFNA4-associated disorder with an anti-EFNA4 antibody-drug conjugate (ADC). The present invention further provides for methods for the treatment of patients with cancer and/or an EFNA4-associated disorder in which an anti-EFNA4 ADC is administered intravenously weekly (QW) or every 3 weeks (Q3W).
-
公开(公告)号：US20170224816A1
公开(公告)日：2017-08-10
申请号：US15501752
申请日：2015-07-29
Applicant: RINAT NEUROSCIENCE CORP.
Inventor： Rachel Marie DeVay JACOBSON , Hong LIANG , David Shelton
IPC: A61K39/395 , A61K31/22 , A61K31/405 , A61K39/29 , A61K31/365
CPC classification number: A61K39/3955 , A61K31/22 , A61K31/365 , A61K31/405 , A61K39/292 , A61K2039/505 , A61K2300/00 , C07K16/40 , C07K2317/76
Abstract: The present invention relates to methods for the treatment of reducing LDL-cholesterol levels in a subject infected with hepatitis C virus (HCV) or at high risk of contracting HCV comprising administration to the subject in need thereof a therapeutically effective amount of an antagonist antibody which specifically binds to a human PCSK9 protein. The subject treatment can be used in the prevention and/or treatment of cholesterol and lipoprotein metabolism disorders, including hypercholesterolemia, dyslipidemia, hyperlipidemia, atherosclerosis, acute coronary syndrome and, more generally, cardiovascular disease (CVD).
-
Patent Agency Ranking
公开(公告)号：US20170088610A1
公开(公告)日：2017-03-30
申请号：US15287246
申请日：2016-10-06
Applicant: RINAT NEUROSCIENCE CORP.
Inventor： ARNON ROSENTHAL , DAVID LOUIS SHELTON , PATRICIA ANN WALICKE
IPC: C07K16/22
CPC classification number: C07K16/22 , A61K39/3955 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
-
公开(公告)号：US20160193356A1
公开(公告)日：2016-07-07
申请号：US14908492
申请日：2014-07-30
Applicant: RINAT NEUROSCIENCE CORP.
Inventor： Santiago Esteban FARIAS , Meritxell GALINDO CASAS , Pavel STROP
IPC: A61K47/48
CPC classification number: A61K47/6803 , A61K47/68 , A61K47/6805 , A61K47/6809 , A61K47/6817
Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates) comprising specific acyl donor glutamine-containing tags and amine donor agents. The invention also provides methods of making such engineered polypeptide conjugates using transglutaminase and methods of using thereof.
Abstract translation: 本发明提供包含特定酰基供体谷氨酰胺标签和胺供体试剂的工程改造的多肽缀合物（例如抗体 - 药物偶联物）。 本发明还提供了使用转谷氨酰胺酶制备这种工程化多肽缀合物的方法及其使用方法。
-
公开(公告)号：US09175093B2
公开(公告)日：2015-11-03
申请号：US13857063
申请日：2013-04-04
Applicant: RINAT NEUROSCIENCE CORP. , PFIZER INC.
Inventor： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Xiayang Qiu , Pavel Strop , Yuli Wang
IPC: A61K39/395 , C07K16/40 , A61K45/06 , A61K39/00
CPC classification number: C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
Abstract translation: 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）结合的拮抗抗体，其抗原结合部分和适体。 还提供了针对肽的抗体，其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病（包括治疗高胆固醇血症）的治疗方法。
-
公开(公告)号：US08715673B2
公开(公告)日：2014-05-06
申请号：US13719214
申请日：2012-12-18
Applicant: Rinat Neuroscience Corp.
Inventor： Davide Luciano Foletti , Javier Fernando Chaparro Riggers , Jacob Eli Gunn Glanville , Lee Mary Beth Shaughnessy , David Louis Shelton , Pavel Strop , Wenwu Zhai
IPC: A61K39/40
CPC classification number: C07K16/1271 , A61K39/40 , A61K2039/505 , C07K2317/34 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K2300/00
Abstract: The present invention provides antagonizing antibodies that bind to S. aureus alpha-toxin. The invention further provides a method of obtaining such antibodies and antibody encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies for the treatment and/or prevention of staphylococcal disease, including, for example, pneumonia, bacteremia, sepsis, eye infection, and abscess.
Abstract translation: 本发明提供了结合金黄色葡萄球菌α-毒素的拮抗性抗体。 本发明还提供了获得这样的抗体和编码抗体的核酸的方法。 本发明还涉及用于这些抗体用于治疗和/或预防葡萄球菌疾病（包括例如肺炎，菌血症，败血症，眼睛感染和脓肿）的治疗方法。
-
公开(公告)号：US20210205463A1
公开(公告)日：2021-07-08
申请号：US17183265
申请日：2021-02-23
Applicant: PFIZER INC. , RINAT NEUROSCIENCE CORP.
Inventor： Russell George DUSHIN , Pavel STROP , Magdalena Grazyna DORYWALSKA , Ludivine MOINE
Abstract: The present invention provides stability-modulated antibody-drug conjugates, stability-modulating linker components used to make these stability-modulated antibody-drug conjugates, therapeutic methods using stability-modulated antibody-drug conjugates, and methods of making stability modulating linkers and stability-modulated antibody-drug conjugates.
-
-
-
-
-
-
-
-
-
Search Results
74
records
(took 0.04 seconds)
